Am J Health Syst Pharm. 2009;66(6):541-561. Shorvon et al. [20] conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and tolerability of levetiracetam ...
Dec. 10, 2002 — Three studies presented on Dec. 9 at the American Epilepsy Society annual meeting suggest new uses for levetiracetam (Keppra). A phase IV trial found that levetiracetam is as effective ...
UCB today announced findings from new studies of the once-daily antiepileptic drug (AED) Keppra XR™ (levetiracetam) extended-release tablets comparing tolerability vs. levetiracetam immediate release ...
ATLANTA, Dec. 3 /PRNewswire/ -- UCB today announced results of a Phase III trial demonstrating that its antiepileptic drug (AED) in development Keppra XR(TM) (levetiracetam) extended-release tablets ...
Xcopri (cenobamate) and Keppra (levetiracetam) are prescribed to treat focal onset seizure. Keppra has additional uses. Keppra comes in several forms, but both drugs come as oral tablets. Keppra is ...
PITTSBURGH, Dec. 11 /PRNewswire-FirstCall/ -- Mylan Inc. (NASDAQ: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the ...
Levetiracetam (LEV) is increasingly used in the treatment of neonatal seizures. The aim of this study was to determine pharmacokinetics in neonates with seizures and to obtain preliminary safety and ...
LOS ANGELES, Oct 4 (Reuters) - Pharmaceutical drug maker Mylan Inc said on Thursday it struck an agreement to settle pending litigation with UCB Societe Anonyme and UCB Pharma Inc over Mylan's generic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results